BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 19937834)

  • 1. Prediction of pharmacokinetic profile of valsartan in humans based on in vitro uptake-transport data.
    Poirier A; Cascais AC; Funk C; Lavé T
    Chem Biodivers; 2009 Nov; 6(11):1975-87. PubMed ID: 19937834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data.
    Poirier A; Cascais AC; Funk C; Lavé T
    J Pharmacokinet Pharmacodyn; 2009 Dec; 36(6):585-611. PubMed ID: 19936896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans.
    Yamashiro W; Maeda K; Hirouchi M; Adachi Y; Hu Z; Sugiyama Y
    Drug Metab Dispos; 2006 Jul; 34(7):1247-54. PubMed ID: 16624871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine.
    Poirier A; Funk C; Scherrmann JM; Lavé T
    Mol Pharm; 2009; 6(6):1716-33. PubMed ID: 19739673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PBPK modeling of irbesartan: incorporation of hepatic uptake.
    Chapy H; Klieber S; Brun P; Gerbal-Chaloin S; Boulenc X; Nicolas O
    Biopharm Drug Dispos; 2015 Nov; 36(8):491-506. PubMed ID: 26037524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
    Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data.
    Kunze A; Huwyler J; Camenisch G; Poller B
    Drug Metab Dispos; 2014 Sep; 42(9):1514-21. PubMed ID: 24989890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OATP1B1/1B3 activity in plated primary human hepatocytes over time in culture.
    Ulvestad M; Björquist P; Molden E; Asberg A; Andersson TB
    Biochem Pharmacol; 2011 Nov; 82(9):1219-26. PubMed ID: 21787759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker.
    Nakagomi-Hagihara R; Nakai D; Kawai K; Yoshigae Y; Tokui T; Abe T; Ikeda T
    Drug Metab Dispos; 2006 May; 34(5):862-9. PubMed ID: 16501004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans.
    Ishiguro N; Maeda K; Kishimoto W; Saito A; Harada A; Ebner T; Roth W; Igarashi T; Sugiyama Y
    Drug Metab Dispos; 2006 Jul; 34(7):1109-15. PubMed ID: 16611857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3.
    Noé J; Portmann R; Brun ME; Funk C
    Drug Metab Dispos; 2007 Aug; 35(8):1308-14. PubMed ID: 17470528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Organic anion transporter 3- and organic anion transporting polypeptides 1B1- and 1B3-mediated transport of catalposide.
    Jeong HU; Kwon M; Lee Y; Yoo JS; Shin DH; Song IS; Lee HS
    Drug Des Devel Ther; 2015; 9():643-53. PubMed ID: 25653502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide.
    Ishiguro N; Maeda K; Saito A; Kishimoto W; Matsushima S; Ebner T; Roth W; Igarashi T; Sugiyama Y
    Drug Metab Dispos; 2008 Apr; 36(4):796-805. PubMed ID: 18180273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes.
    Ménochet K; Kenworthy KE; Houston JB; Galetin A
    Drug Metab Dispos; 2012 Sep; 40(9):1744-56. PubMed ID: 22665271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium fluorescein is a probe substrate for hepatic drug transport mediated by OATP1B1 and OATP1B3.
    De Bruyn T; Fattah S; Stieger B; Augustijns P; Annaert P
    J Pharm Sci; 2011 Nov; 100(11):5018-30. PubMed ID: 21837650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats.
    Scotcher D; Melillo N; Tadimalla S; Darwich AS; Ziemian S; Ogungbenro K; Schütz G; Sourbron S; Galetin A
    Mol Pharm; 2021 Aug; 18(8):2997-3009. PubMed ID: 34283621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, data analysis, and simulation of in vitro drug transport kinetic experiments using a mechanistic in vitro model.
    Poirier A; Lavé T; Portmann R; Brun ME; Senner F; Kansy M; Grimm HP; Funk C
    Drug Metab Dispos; 2008 Dec; 36(12):2434-44. PubMed ID: 18809732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic uptake and excretion of (-)-N-{2-[(R)-3-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a novel if channel inhibitor, in rats and humans.
    Umehara K; Iwai M; Adachi Y; Iwatsubo T; Usui T; Kamimura H
    Drug Metab Dispos; 2008 Jun; 36(6):1030-8. PubMed ID: 18332079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril.
    Maeda K; Ieiri I; Yasuda K; Fujino A; Fujiwara H; Otsubo K; Hirano M; Watanabe T; Kitamura Y; Kusuhara H; Sugiyama Y
    Clin Pharmacol Ther; 2006 May; 79(5):427-39. PubMed ID: 16678545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data.
    Jones HM; Barton HA; Lai Y; Bi YA; Kimoto E; Kempshall S; Tate SC; El-Kattan A; Houston JB; Galetin A; Fenner KS
    Drug Metab Dispos; 2012 May; 40(5):1007-17. PubMed ID: 22344703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.